retatrutide phase 2 trial type 2 diabetes weight loss 2024 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Retatrutide study sees significant weight

Protocol 3: long-term maintenance (for persistent mild symptoms) Goal: Comfortable long-term adherence with minimal GI disruption

This peptide dosage chart tells you exactly how much of each peptide to take, how often, and when

In a 2018 analysis of clinical trial data, several researchers working with Novo Nordisk, the drugmaker for Ozempic and Wegovy, found that the drugs were safe and effective in adults over age 65, but noted that older adults reported discontinuation due to gastrointestinal issues at a higher rate than younger participants did

GLP-1 receptor agonists offer a promising solution for T2DM management, aiding glycemic control while addressing the weight management challenges associated with diabetes